CAS 62540-08-3

2H-Indol-2-one, 1,3-dihydro-3-(2-thienylmethylene)-

Description:

2H-Indol-2-one, 1,3-dihydro-3-(2-thienylmethylene)-, with the CAS number 62540-08-3, is a chemical compound that belongs to the class of indole derivatives. This compound features a fused indole ring system, which is characterized by a bicyclic structure containing a benzene ring fused to a pyrrole ring. The presence of the thienylmethylene group introduces a sulfur-containing heterocyclic component, which can influence the compound's reactivity and biological activity. Typically, such compounds exhibit a range of properties, including potential pharmacological effects, due to their structural motifs. They may possess antioxidant, anti-inflammatory, or antimicrobial activities, making them of interest in medicinal chemistry. The compound's solubility, stability, and reactivity can vary based on its functional groups and the overall molecular structure. As with many organic compounds, the specific characteristics such as melting point, boiling point, and spectral properties would need to be determined experimentally or sourced from reliable databases for precise applications in research or industry.

Formula: C₁₃H₉NOS

Synonyms:

• SU5208

2H-Indol-2-one, 1,3-dihydro-3-(2-thienylmethylene)-

CAS: 62540-08-3

Formula: C₁₃H₉NOS

Purity: 98%

Color and Shape: Solid

Molecular weight: 227.2817

Ref: IN-DA01GS4I

SU5208

CAS: 62540-08-3

SU5208

Purity: ≥98%

Molecular weight: 227.28g/mol

Ref: 54-BUP08028

SU5208

CAS: 62540-08-3

SU5208 (3-[(Thien-2-yl)methylene]-2-indolinone) is a compound with bioactivity.SU5208 inhibits vascular endothelial growth factor receptor-2 (VEGFR2).

Formula: C₁₃H₉NOS

Purity: 99.62%

Color and Shape: Solid

Molecular weight: 227.28

Ref: TM-T22432

Su5208

CAS: 62540-08-3

Su5208 is a potent and selective kinase inhibitor. It binds to the ATP binding site of the tyrosine kinase receptor and inhibits receptor tyrosine kinase activity. Su5208 has been shown to inhibit the growth of human cancer cells in vitro and in vivo, as well as modulate the immune system by regulating T cell activation. This drug has been shown to be efficacious with low toxicity in animal models of cancer, making it a potential candidate for cancer treatment. Su5208 is also an oxindole-based compound that can be synthesized from a readily available starting material.
Su5208 contains a single crystal form with a space group P2(1)2(1)2(1). The molecular geometry consists of two molecules per asymmetric unit, which have an R-factor of 0.049 (Rfree=0.053). The molecule contains two distinct binding sites, which are each occupied by one molecule of Su5208.

Formula: C₁₃H₉NOS

Purity: Min. 95%

Molecular weight: 227.28 g/mol

Ref: 3D-MCA54008